Safety of Large Field (>20cm2) Photodynamic Therapy Using 10% Aminolevulinic Acid Hydrochloride Nanoemulsion Gel Comparing Blue to Red Light Illumination
Dodds, A., A. Chia, and S. Shumack, “Actinic keratosis: rationale and management.” Dermatol Ther (Heidelb). 2014. 4(1):11-31.
Reinhold U, Dirschka T, Ostendorf R, Aschoff R, Berking C, Philipp-Dormston WG, Hahn S, Lau K, Jäger A, Schmitz B, Lübbert H, Szeimies RM. “A randomized, double-blind, phase III, multicentre study to evaluate the safety and efficacy of BF-200 ALA (Ameluz(®) ) vs. placebo in the field-directed treatment of mild-to-moderate actinic keratosis with photodynamic therapy (PDT) when using the BFRhodoLED(®) lamp.” Br J Dermatol. 2016:175(4):696-705.
Reinhold U. “A review of BF-200 ALA for the photodynamic treatment of mild-to-moderate actinic keratosis.” Future Oncol. 2017:13(27):2413-2428
Nestor et al. “Safety and efficacy of aminolevulinic acid 10% topical gel versus aminolevulinic acid 20% topical solution followed by blue-light photodynamic therapy for the treatment of actinic keratosis on the
face and scalp: a randomized, double-blind study.” J Clin Aesthet Dermatol. 2019;12:32-38.
Warren CB, Lohser S, Wene LC, Pogue BW, Bailin PL, Maytin EV. Noninvasive fluorescence monitoring of protoporphyrin IX production and clinical outcomes in actinic keratoses following short-contact
application of 5-aminolevulinate. J Biomed Opt. 2010;15(5):051607.
Abstract - 77 Poster PDF - 12
- There are currently no refbacks.